[go: up one dir, main page]

WO2012014971A1 - Bactérie lactique ayant un effet d'amélioration du syndrome métabolique - Google Patents

Bactérie lactique ayant un effet d'amélioration du syndrome métabolique Download PDF

Info

Publication number
WO2012014971A1
WO2012014971A1 PCT/JP2011/067239 JP2011067239W WO2012014971A1 WO 2012014971 A1 WO2012014971 A1 WO 2012014971A1 JP 2011067239 W JP2011067239 W JP 2011067239W WO 2012014971 A1 WO2012014971 A1 WO 2012014971A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
lactobacillus
strain
adiponectin
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2011/067239
Other languages
English (en)
Japanese (ja)
Inventor
利光孝之
池上秀二
伊藤裕之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Co Ltd
Original Assignee
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Co Ltd filed Critical Meiji Co Ltd
Priority to CN201180037354.8A priority Critical patent/CN103314099B/zh
Priority to HK13111466.7A priority patent/HK1184187B/xx
Priority to JP2011551729A priority patent/JP5076029B2/ja
Publication of WO2012014971A1 publication Critical patent/WO2012014971A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Definitions

  • the present invention relates to a lactic acid bacterium having an improvement effect on metabolic syndrome, and a pharmaceutical composition and a food composition containing the lactic acid bacterium.
  • Non-Patent Documents 1 to 3 Adiponectin secreted from adipocytes acts on muscle cells to enhance sugar transport through activation of IRS-1 and PI3-kinase, and expression of fatty acid transport protein type 1 (FATP-1) and AMP-kinase It is known that insulin sensitivity is increased by increasing fatty acid oxidation and excretion (Non-patent Document 4).
  • Adiponectin is also known to have an anti-inflammatory effect on the chronic inflammatory state of adipose tissue, and is known to improve insulin resistance by suppressing the production of TNF ⁇ (Non-patent Document 5). Therefore, increasing the secretion of adiponectin from adipocytes is thought to be important for improving metabolic syndrome including obesity and diabetes. In recent years, research targeting the functional control of adipocytes has attracted attention. It has become a target for the function of food factors (Non-Patent Document 6).
  • Non-Patent Documents 7 to 11 Further, regarding the relationship between adiponectin and IL-10, it has been shown that when adiponectin is added to human primary cultured macrophage cells, the amount of IFN ⁇ secretion decreases and the amount of IL-10 secretion increases (non-patent document). 12).
  • Patent Document 1 naringenin chalcone derived from tomato extract
  • Patent Document 2 proanthocyanidins derived from grape extract
  • Patent Document 3 product-derived polyphenols
  • the present inventors When searching for lactic acid bacteria that improve metabolic syndrome, the present inventors have a stronger improvement effect by adding not only adiponectin as an index but also an index indicating suppression of inflammation induced by metabolic syndrome. I thought it could be expected. Then, it discovered that it was necessary to establish the new test system for searching the target lactic acid bacteria. The present inventors then evaluated the ability of adipocytes to produce anti-inflammatory cytokines such as IL-10 secreted from immune system cells in addition to the ability to produce adiponectin in an in vitro test system. As a result of finding that probiotics capable of improving metabolic syndrome including insulin resistance can be searched by controlling the function of, and further earnestly researching it, the present invention has been completed.
  • the present invention relates to a genus Lactobacillus that increases adiponectin production for adipocytes and increases production of inflammatory immunity-related cytokines for bone marrow-derived dendritic cells and / or macrophages.
  • the present invention also relates to the aforementioned Lactobacillus genus, wherein the inflammatory immunity-related cytokine is IL-10.
  • this invention relates to the said Lactobacillus genus microbe which is Lactobacillus plantarum.
  • the present invention also relates to a Lactobacillus plantarum OLL2712 strain (Accession Number: FERM BP-11262). Furthermore, this invention relates to the culture of the said microbe, or its processed material.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising one or more selected from the group consisting of the above-mentioned fungus, the above-mentioned culture and its processed product. Furthermore, this invention relates to the said pharmaceutical composition for suppressing accumulation
  • the Lactobacillus genus of the present invention can increase adiponectin production with respect to adipocytes, and can increase anti-inflammatory cytokine production with respect to bone marrow-derived dendritic cells and / or macrophages.
  • adiponectin in addition to increasing the production of adiponectin, it is also possible to increase the production of anti-inflammatory cytokines independent of adiponectin, and to improve the metabolic syndrome with a highly reliable complex approach Play.
  • FIG. 1a is a graph showing the results of the expression level of adiponectin mRNA when pioglitazone (Pio) and / or TNF ⁇ (TNF) is added to 3T3-L1 cells.
  • FIG. 1b is a graph showing the results of mRNA expression level of Cu, Zn-SOD when pioglitazone (Pio) and / or TNF ⁇ (TNF) is added to 3T3-L1 cells.
  • FIG. 2a is a graph showing the result of the expression level of adiponectin mRNA in 3T3-L1 cells when insulin resistance was induced by addition of TNF ⁇ .
  • FIG. 1a is a graph showing the results of the expression level of adiponectin mRNA when pioglitazone (Pio) and / or TNF ⁇ (TNF) is added to 3T3-L1 cells.
  • FIG. 2a is a graph showing the result of the expression level of adiponectin
  • FIG. 2b is a graph showing the results of mRNA expression levels of Cu, Zn-SOD in 3T3-L1 cells when insulin resistance was induced by addition of TNF ⁇ .
  • FIG. 2c is a graph showing the results of the expression level of IL-6 mRNA in 3T3-L1 cells when insulin resistance was induced by addition of TNF ⁇ .
  • FIG. 2d is a graph showing the results of mRNA expression level of MCP-1 in 3T3-L1 cells when insulin resistance was induced by addition of TNF ⁇ .
  • FIG. 3a is a graph showing the results of adiponectin mRNA expression level in 3T3-L1 cells when insulin resistance was not induced by addition of TNF ⁇ .
  • FIG. 3b is a graph showing the results of mRNA expression levels of Cu, Zn-SOD in 3T3-L1 cells when insulin resistance was not induced by addition of TNF ⁇ .
  • FIG. 3c is a graph showing the results of the expression level of IL-6 mRNA in 3T3-L1 cells when insulin resistance was not induced by addition of TNF ⁇ .
  • FIG. 4a is a graph showing the results of the effect of dead lactic acid bacteria on IL-10 production of mouse bone marrow-derived dendritic cells (BMDC).
  • FIG. 4b is a graph showing the results of the effect of dead lactic acid bacteria on IL-12 (p70) production of mouse bone marrow-derived dendritic cells (BMDC).
  • FIG. 5a is a graph showing the results of the effect of dead lactic acid bacteria on IL-6 production of mouse macrophages J774.1.
  • FIG. 5b is a graph showing the results of the effect of dead lactic acid bacteria on IL-10 production of mouse macrophages J774.1.
  • FIG. 5c is a graph showing the results of the effect of dead lactic acid bacteria on IL-12 (p40) production of mouse macrophages J774.1.
  • FIG. 6 is a graph showing the effect of lactic acid bacteria skim milk culture on blood adiponectin concentration in diabetic / obese model mice (KKAy mice). Mean values ⁇ SE are shown.
  • FIG. 5a is a graph showing the results of the effect of dead lactic acid bacteria on IL-6 production of mouse macrophages J774.1.
  • FIG. 5b is a graph showing the results of the effect of dead lactic acid bacteria on IL-10 production of mouse macrophages J774.1.
  • FIG. 5c is a graph showing the results of the
  • FIG. 7 is a graph showing the effect of lactic acid bacteria skim milk culture on the amount of adiponectin mRNA in visceral adipose tissue-derived adipocytes of diabetic / obese model mice (KKAy mice). Mean values ⁇ SE are shown.
  • FIG. 8 is a graph showing the results of the effect of lactic acid bacteria skim milk culture on visceral fat weight of diabetic / obese model mice (KKAy mice). Mean values ⁇ SE are shown.
  • FIG. 9 is a graph showing the results of the effects of lactic acid bacteria skim milk culture on blood triglyceride levels in diabetic / obese model mice (KKAy mice). Mean values ⁇ SE are shown.
  • FIG. 10 is a graph showing the results of the influence of a lactic acid bacteria skim milk culture on blood HbA1c values in diabetic / obese model mice (KKAy mice). Mean values ⁇ SE are shown.
  • the Lactobacillus genus of the present invention increases adiponectin production relative to adipocytes.
  • the adipocytes are not particularly limited as long as they are established in vitro (in vitro).
  • mouse fibroblast-derived 3T3-L1 cells known as adipocyte models are known. Can be mentioned.
  • the Lactobacillus genus of the present invention usually increases the production of inflammatory immunity-related cytokines to cells that do not produce adiponectin, such as bone marrow-derived dendritic cells and macrophages.
  • adiponectin such as bone marrow-derived dendritic cells and macrophages.
  • the production of inflammatory immune related cytokines is increased against bone marrow derived dendritic cells and / or macrophages. It is confirmed in vitro that the Lactobacillus genus of the present invention increases adiponectin production to adipocytes and / or increases production of inflammatory immune-related cytokines to cells that do not produce adiponectin, respectively. be able to.
  • the inflammatory immunity related cytokine includes all cytokines related to inflammatory reaction.
  • Inflammatory immunity-related cytokines can be broadly classified into cytokines that have the property of promoting inflammatory responses and cytokines that have the property of suppressing inflammatory responses.
  • Cytokines having the property of promoting an inflammatory response include, but are not limited to, for example, IL-1 ⁇ , IL-1 ⁇ , IL-6, IL-7, IL-8, IL-12, IL-13
  • Inflammatory cytokines such as IL-17, IL-18, IFN ⁇ , MCP-1, TNF ⁇ , and LIF.
  • Cytokines having the property of suppressing inflammatory reactions include, but are not limited to, for example, anti-inflammatory cytokines such as IL-4, IL-10, and TGF- ⁇ , and antiviral cytokines such as IFN ⁇ and IFN ⁇ Etc.
  • Preferred inflammatory immunity-related cytokines are those that are associated with metabolic syndrome, such as IL-10 and IL-6, and particularly preferably IL-10.
  • production increased means adiponectin (protein, mRNA) expressed by a target cell upon stimulation of a test cell (live or dead) or a sample such as a culture or culture supernatant thereof. This means that the value serving as an index such as the expression level of inflammatory immune-related cytokines increases beyond the range of statistical errors.
  • any statistical analysis method known to those skilled in the art may be used, and it is not limited thereto, and examples thereof include Student's t test and Mann-Whitney U test.
  • Lactobacillus included in the present invention examples include, but are not limited to, for example, Lactobacillus delbrueckii subsp. Burgaricus, Lactobacillus delbrueckii subsp. lactis, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus amylovorus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus oris, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus fermentum, Lactobacillus brevis, Lactobacillus plantarum and the like, preferably Lactobacillus amylovorus, Lactobacillus plantarum and the like, particularly preferably Lactobacillus plantarum.
  • the Lactobacillus genus of the present invention is preferably resistant to gastric acid or bile acids. Due to such resistance, for example, as a food composition containing lactic acid bacteria, it can reach the intestine with live bacteria without using an enteric coating material, etc., improving the intestinal environment and continuously improving metabolic syndrome And / or a preventive effect.
  • Lactobacillus plantarum OLL2712 (also referred to as strain 23 in the present specification) of the present invention is deposited at the National Institute of Advanced Industrial Science and Technology under the accession number: FERM BP-11262, and has the following characteristics: It is a plantarum fungus.
  • the subject for improving and / or preventing metabolic syndrome is an animal suffering from or possibly having a disease associated with metabolic syndrome including obesity and diabetes (for example, human, domestic animal) Species, wild animals, pets, etc.).
  • the metabolic syndrome to be improved and / or prevented in the present invention includes, for example, metabolic syndrome such as diabetes, obesity (particularly visceral fat obesity), high blood pressure, high blood sugar, dyslipidemia, arteriosclerosis and the like. It may include diseases that are implicated.
  • the Lactobacillus genus of the present invention When the Lactobacillus genus of the present invention is used for pharmaceuticals or foods for the improvement and / or prevention of metabolic syndrome, live bacteria, killed bacteria, cultures and processed products thereof can be used.
  • the culture is a culture supernatant or a medium component after completion of cultivation of the Lactobacillus genus of the present invention, and the processed product is not particularly limited as long as it is derived from the culture. And the like obtained by processing such as concentration, pasting, spray drying, freeze drying, vacuum drying, drum drying, liquefaction, dilution and crushing. For these processes, known methods can be used as appropriate.
  • the genus Lactobacillus of the present invention may be live or dead.
  • the Lactobacillus genus of the present invention for example, a medium component, an additive suitable for oral tube feeding, and a solvent such as water, carbohydrates, proteins, lipids, vitamins Biopharmaceutical trace metals, fragrances, pharmaceutically acceptable carriers, food additives, and other optional components can be added to form pharmaceutical compositions and food compositions.
  • a medium component such as water, carbohydrates, proteins, lipids, vitamins Biopharmaceutical trace metals, fragrances, pharmaceutically acceptable carriers, food additives, and other optional components can be added to form pharmaceutical compositions and food compositions.
  • the pharmaceutical composition of the present invention typically increases the production of adiponectin on adipocytes and increases the production of inflammatory immune-related cytokines on bone marrow-derived dendritic cells and / or macrophages 1 type or 2 types or more selected from the culture and the processed product.
  • a pharmaceutical composition improves the intestinal environment of an ingested individual and has an improving effect on metabolic syndrome.
  • the pharmaceutical composition of the present invention can be used for effectively suppressing the accumulation of visceral fat.
  • the route of administration of the pharmaceutical composition is not particularly limited, and includes oral or parenteral administration, and examples thereof include oral administration, tube administration, and enteral administration. Oral administration is preferred from the viewpoint of convenience and safety.
  • the dosage form is not particularly limited, and can be appropriately selected depending on the administration route.
  • Oral preparations can be made into various known dosage forms, such as granules, powders, tablets, pills, capsules, solutions, syrups, emulsions, suspensions, lozenges, and the like. can do.
  • enteric preparation it can be more efficiently transported to the intestine without receiving the effect of gastric acid.
  • parenteral administration include administration in the form of injections.
  • the Lactobacillus genus bacteria of this invention, its culture, or its processed material can also be locally administered to the area
  • Carriers that can be used in the pharmaceutical composition of the present invention include surfactants, excipients, coloring agents, flavoring agents, preservatives, stabilizers, buffers, suspending agents, isotonic agents, binders, and disintegrants.
  • Lubricants, fluidity promoters, flavoring agents and the like are listed as pharmaceutically acceptable carriers, and other commonly used carriers can be used as appropriate.
  • the cell concentration is not particularly limited, but when used as a concentrate, 2 ⁇ 10 10 cells / g or more, when used as a dry product, 3 ⁇ 10 It is preferable to set it to 11 pieces / g or more.
  • the amount of Lactobacillus spp., Its culture or processed product thereof is not particularly limited, but can be appropriately adjusted according to the dosage form, symptoms, body weight, use and the like.
  • the daily intake of the pharmaceutical composition of the present invention is not particularly limited, but can be appropriately adjusted according to age, symptoms, body weight, use and the like. Typically, 0.1 to 10000 mg / kg body weight can be taken, preferably 0.1 to 1000 mg / kg body weight, more preferably 0.1 to 300 mg / kg body weight.
  • the food composition of the present invention typically increases the production of adiponectin on adipocytes and increases the production of inflammatory immune related cytokines on bone marrow-derived dendritic cells and / or macrophages 1 type or 2 types or more selected from the culture and the processed product.
  • a food composition improves the intestinal environment of the ingested individual and has an improvement effect on the metabolic syndrome.
  • the food composition of the present invention can be used to effectively suppress visceral fat accumulation.
  • the food composition of the present invention further includes carbohydrates, proteins, lipids, vitamins, biologically essential trace metals (manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), fragrances, and other ingredients as long as they do not interfere with the growth of lactic acid bacteria. Things can be included.
  • saccharide examples include saccharides, processed starch (in addition to dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
  • protein examples include whole milk powder, skim milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, ⁇ -lactoglobulin , ⁇ -lactalbumin, lactoferrin, soy protein, egg protein, meat protein and other animal and vegetable proteins, hydrolysates thereof; butter, milk minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc. And various milk-derived components.
  • Examples of lipids include animal oils such as lard and fish oil, fractionated oils thereof, hydrogenated oils and transesterified oils; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples include vegetable oils such as hydrogenated oils and transesterified oils.
  • vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline.
  • Examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium.
  • the food composition of the present invention may be a functional food, a food for specified health use, a food for specific use, a functional nutrition food, a health food, a food for nursing care, and a confectionery, lactic acid bacteria beverage, cheese, It may be a dairy product such as yogurt or a seasoning.
  • the shape of the food and drink there is no limitation on the shape of the food and drink, and it can take any form of food or drink that can be distributed normally, such as solid, liquid, liquid food, jelly, tablet, granule, capsule, and various foods (milk, Soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crusts, formula milk, liquid foods, food for the sick, nutritional foods, frozen foods, processed foods and other commercial foods) .
  • Manufacture of the said food / beverage products can be performed by those skilled in the art.
  • the Lactobacillus genus of the present invention can be processed into general foods and drinks including dairy products and fermented milk, as well as starters for producing dairy products and fermented milk such as yogurt and cheese. It is also possible to use as.
  • a starter other microorganisms may be mixed as long as there is no hindrance to the survival and growth of the Lactobacillus genus of the present invention and as long as there is no hindrance to dairy production.
  • Lactobacillus delbrueckii subsp for example, Lactobacillus delbrueckii subsp.
  • Bulgaricus, Streptococcus which are the main bacterial species as lactic acid bacteria for yogurt It may be mixed with thermophilus, Lactobacillus acidophilus, etc. In addition, it can be mixed with bacterial species generally used for yogurt or cheese to form a starter.
  • Production of dairy products and fermented milk using the starter can be performed according to a conventional method.
  • plain yogurt can be produced by mixing the above starter with milk or a dairy product cooled after heating, mixing, homogenizing, and sterilizing, and then fermenting and cooling.
  • the starter is appropriately selected according to the dairy product and fermented milk to be produced. Specifically, for example, a lactic acid bacterium or bifidobacteria belonging to the genus Streptococcus, Lactobacillus, Lactococcus, Leuconostoc and Pediococcus is used. Can be used.
  • Streptococcus lactis Streptococcus cremoris, Streptococcus diacetylactis, Streptococcus thermophilus, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus delbrueckii subsp.bulgaricus, Lactobacillus delbrueckii subsp.
  • lactis Lactobacillus gasseri, Lactobacillus mucosae, Lactobacillus murinus, Lactobacillus plantarum, Lactobacillus oris, Lactobacillus reuteri and Lactobacillus Lactic acid bacteria such as rhamnosus, Bifidobacterium longum, Bifidobacterium bifidum and Bifidobacterium
  • a microorganism such as Bifidobacterium such as breve can be used as a starter. More preferably, Lactobacillus delbrueckii subsp.bulgaricus, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. lactis can be used as starters. When these microorganisms are used as starters, they can be used alone or in combination of two or more as required.
  • a method for isolating these microorganisms from nature and fermented milk is known.
  • already isolated microorganisms can be obtained by distribution from a cell bank or the like.
  • lactic acid bacteria starters are commercially available.
  • Several products are sold depending on the pH and physical properties of the produced fermented milk.
  • the physical properties of fermented milk refer to hardness, smoothness, and the like.
  • the microorganism added to the raw milk as a mixed starter can be selected from microorganisms deposited in the cell bank.
  • desirable strains that can be utilized in mixed starters include Lactobacillus bulgaricus JCM 1002T and Streptococcus Streptococcus, a lactic acid bacteria starter consisting of a mixed culture of thermophilus ATCC 19258 thermophilus OLS 3059 (FERM BP-10740), Streptococcus thermophilus OLS3294 (NITE P-77), Streptococcus thermophilus OLS3059 (FERMP-15487), Lactobacillus delbrueckii subspecies bulgaricus OLL 1073R-1 (FERM BP-10741), Lactobacillus delbrueckii and a lactic acid bacteria starter comprising a mixed culture of subspecies bulgaricus OLL 1255 (NITE BP-76) and Lactobacillus delbrueckii subspecies bulgaricus OLL
  • raw milk may be added with one or more selected from lactic acid bacteria and yeasts other than these lactic acid bacteria.
  • Lactobacillus bulgaricus L. bulgaricus
  • Streptococcus thermophilus S. thermophilus
  • additional microorganisms can also be mixed in this mixing starter in consideration of the fermentation temperature and fermentation conditions of the target fermented milk.
  • Other microorganisms such as Lactobacillus gasseri (L. gasseri), Lactobacillus plantarum, and Bifidobacterium can be shown as microorganisms to be additionally mixed in the mixed starter.
  • the cell concentration is not particularly limited, but when used as a concentrate, 2 ⁇ 10 10 cells / g or more, when used as a dry product, 3 ⁇ 10 It is preferable to set it to 11 pieces / g or more.
  • the content of the Lactobacillus genus of the present invention in the food composition (as the amount of dry substance) is 0.01 to 100 w / w%, more preferably 1 to 10% in the solid content of the food composition. 80 w / w%, more preferably 10 to 40 w / w%.
  • the amount of Lactobacillus sp., Its culture or processed product thereof is not particularly limited, but can be appropriately adjusted according to the dosage form, symptoms, body weight, use and the like.
  • the daily intake of the food composition of the present invention is not particularly limited, but can be appropriately adjusted according to age, symptoms, body weight, use and the like.
  • 0.1 to 10000 mg / kg body weight can be taken, preferably 0.1 to 1000 mg / kg body weight, more preferably 0.1 to 300 mg / kg body weight.
  • the dry substance amount of the Lactobacillus genus of the present invention is 0.1 to 100 mg / kg body weight and 0.5 to 10 mg / kg body weight, and the number of the Lactobacillus genus of the present invention is 10 6 to 10 12. Examples are 10 7 to 10 11 , and 10 8 to 10 10 .
  • Example 1 Construction of screening system using mouse fibroblast-derived 3T3-L1 cells Screening system for lactic acid bacteria having anti-obesity / anti-diabetic activity using mouse fibroblast-derived 3T3-L1 cell line which is a model of adipocytes was established.
  • Test strains From about 270 strains isolated from healthy human feces, 20 strains (strain numbers 1 to 19, 23) having excellent resistance to gastric acid or bile acids were selected and used. In addition to these, a total of 23 strains shown in Table 1 below were used, in which 3 strains (strain numbers 20 to 22) having high immunomodulating activity were added from many strains isolated from various fermented milks.
  • Lactic acid bacteria are prepared from skim milk powder medium (Table 2) and MRS medium (Lactobacilli MRS Broth (Difco, No. 288130)) and cultured at 37 ° C.
  • the culture supernatant was prepared by first cultivating lactic acid bacteria in skim milk powder medium and MRS medium at 37 ° C. for 18 hours, collecting the supernatant, and then passing the collected supernatant through a 0.22 ⁇ m filter. It was.
  • the culture supernatant was stored at ⁇ 20 ° C.
  • 3T3-L1 cell line purchased from DS Pharma Biomedical
  • DMEM fetal calf serum
  • FCS fetal calf serum
  • differentiation medium 10% FCS-containing DMEM, 10 ⁇ g / ml insulin, 2.5 ⁇ M dexamethasone, 3 -Isobutyl-1-methylxanthine (0.5 mM).
  • the cells were further cultured in the maintenance medium (10 ⁇ g / ml insulin in 10% FCS-containing DMEM) for 48 hours, and thereafter cultured in DMEM containing 10% FCS. Cells 7 days after replacement with maintenance medium were used for the assay.
  • the adipocyte differentiation / maintenance reagent (AdipoInducer Reagent (for animal cell)) was purchased from Takara Bio Inc.
  • the composition of the added reagent for differentiation medium was an insulin solution (10 ⁇ g / ml), a dexamethasone solution (2.5 ⁇ M), and a 3-isobutyl-1-methylxanthine solution (0.5 mM).
  • the composition of the addition reagent for the maintenance medium was an insulin solution (10 ⁇ g / ml).
  • the medium was replaced with a medium supplemented with 1% of lactic acid bacteria culture supernatant 22 hours before collecting the cells, and 2 hours later, 10 ng / ml of TNF ⁇ (purchased from Sigma-Aldrich) was added.
  • pioglitazone pioglitazone, sold by Wako Pure Chemical Industries, Ltd., manufacturer: Alexis
  • used as a therapeutic agent for diabetes was added to a concentration of 10 ⁇ M to serve as a positive control.
  • the cell lysate was collected with TRIzol reagent (Invitrogen, purchased from Life Technologies) and real-time PCR system (Applied Biosystems, Life The gene expression level was measured by Technologies).
  • control is 3T3-L1 cells to which nothing is added
  • TNF10 ng / ml is “Pio 10 ⁇ M for 3T3-L1 cells to which TNF ⁇ is added at 10 ng / ml.
  • Is for 3T3-L1 cells supplemented with 10 ⁇ M pioglitazone, and“ Pio + TNF ” is for 3T3-L1 cells co-added with 10 ⁇ M pioglitazone and 10 ng / ml TNF ⁇ .
  • catalase which is another representative antioxidant factor (data not shown).
  • Example 2 Anti-obesity and anti-diabetic activity of various lactic acid bacteria skim milk culture supernatants Adiponectin in which the skim milk milk culture supernatants and MRS culture supernatants of 22 strains of lactic acid bacteria of Nos. 1-21 and 23 in Table 1 are 3T3-L1 cells The effect on the expression level was evaluated.
  • strain 12 a skim milk powder culture supernatant of Lactobacillus amylovorus MEP222812 (hereinafter referred to as strain 12), Lactobacillus plantarum MEP222817 (hereinafter referred to as strain 17), and Lactobacillus plantarum OLL2712 (hereinafter referred to as strain 23) of number 23 was obtained. It showed the effect of significantly increasing the expression level of adiponectin in 3T3-L1 cells. Furthermore, as a result of confirming reproducibility for these three strains, it was found that two strains, strain 17 and strain 23, showed stable effects.
  • strain 22 Lactobacillus delbrueckii subsp. Bulgaricus MEP222822 (hereinafter referred to as strain 22), which has been confirmed to have anti-inflammatory effects such as markedly inducing IL-10 production in mouse bone marrow-derived BMDC cells, is cultured on skim milk powder. Qing was also evaluated at the same time. The results of evaluation in a system in which insulin resistance was induced by TNF ⁇ (10 ng / ml) are shown in FIGS. In FIGS.
  • control is 3T3-L1 cells to which nothing has been added
  • salted milk powder + TNF is a skim milk powder medium and 3T3-L1 cells to which TNF ⁇ is added at 10 ng / ml.
  • strain 22 + TNF is a non-fat dry milk culture supernatant obtained by culturing strain 22 and 3T3-L1 cells supplemented with 10 ng / ml TNF ⁇
  • strain 17 + TNF is a non-fat dry milk culture supernatant obtained by culturing strain 17
  • strain 23 + TNF is “pio + TNF” in the case of the skim milk culture supernatant obtained by culturing strain 23 and 3T3-L1 cells to which 10 ng / ml of TNF ⁇ is added.
  • strains 17 and 23 significantly increased the expression level of adiponectin in 3T3-L1 cells. Furthermore, strain 23 significantly suppressed IL-6 expression and significantly increased Cu, Zn-SOD expression. On the other hand, strain 22 significantly increased the expression level of IL-6, but did not affect the expression levels of other genes. Pioglitazone did not suppress IL-6 but significantly suppressed MCP-1. On the other hand, the skim milk culture supernatant of strain 23 suppressed IL-6 and did not affect MCP-1. The culture supernatant of strain 22 significantly increased IL-6.
  • the skim milk culture supernatant of strain 23 increases the adiponectin expression level by a mechanism different from that of pioglitazone.
  • the mechanism of action of pioglitazone is a ligand for the nuclear receptor type transcription factor PPAR ⁇ , and changes the expression of genes that are transcriptionally regulated by PPAR ⁇ such as adiponectin. Since PPAR ⁇ is highly expressed especially in adipocytes, it is considered that adipocytes are the main target cells of pioglitazone.
  • FIGS. 3a to 3c The results of a similar study in a system that does not induce insulin resistance by the addition of TNF ⁇ are shown in FIGS. 3a to 3c.
  • control is 3T3-L1 cells to which nothing is added
  • skim milk powder is 3T3-L1 cells to which skim milk medium is added
  • strain 17 is In the case of 3T3-L1 cells added with the skim milk powder culture supernatant obtained by culturing the strain 17, “strain 23” is the case of 3T3-L1 cells added with the skim milk powder culture supernatant obtained by culturing the strain 23.
  • strain 23 significantly increased the expression levels of adiponectin and Cu, Zn-SOD in 3T3-L1 cells even in the system without addition of TNF ⁇ . Further, although the expression level of IL-6 was not significant, the average value was suppressed by about 20%. On the other hand, strain 17 had no significant effect on any gene expression level.
  • the non-fat dry milk culture supernatant of strain 23 increased the adiponectin expression level and suppressed the IL-6 expression level, suggesting the possibility of having anti-obesity / anti-diabetic effects.
  • the non-fat dry milk culture supernatant of strain 22 has no such activity, and it was shown that strain 23 has excellent characteristics in terms of utilization of non-fat dry milk culture as an anti-obesity / anti-diabetic material.
  • GM-CSF Granulocyte Macrophage RPMI (Roswell Park Memorial) with colony-stimulating factor Institute) -medium 1640 was cultured in 10 ml, and after 3 days, 5 ml of RPMI-medium 1640 containing GM-CSF was added. Five days later, floating cells considered to be BMDC were collected, seeded in a 96-well plate at 1 ⁇ 10 5 cells / well, and lactic acid bacteria killed at each concentration were added simultaneously. After 24 hours, the culture supernatant was collected, and the concentrations of IL-10 and IL-12 (p70) were quantified using a mouse ELISA kit. Antibodies and ELISA kits were purchased from Becton, Dickinson and Company.
  • strain 4 The effect of the three freeze-dried dead cells on the cytokine production ability of BMDC cells was examined.
  • a strain 22 having known activity and a dead cell of Lactobacillus gasseri MEP222804 (hereinafter referred to as strain 4) were used. Fig.
  • strain 12 is a BMDC cell to which a dead cell of strain 12 is added
  • strain 17 is a BMDC cell to which a dead cell of strain 17 is added
  • 23 is a BMDC cell to which a dead cell of strain 23 is added
  • Strain 22 is a BMDC cell to which a dead cell of strain 22 is added
  • Strain 4 is a dead cell of strain 4
  • the dead cells of strain 23 showed IL-10 and IL-12 production-inducing activity comparable to that of strain 22.
  • the dead cells of strain 17 had very low IL-10 and IL-12 (p70) production-inducing activity compared to these, and the dead cells of strain 12 showed little activity.
  • Example 4 Assay using mouse macrophage J774.1 cell line
  • Mouse macrophage J774.1 cells purchased from Riken Cell Bank (RCB) were cultured in RPMI medium containing 10% FCS and passaged every 3 days.
  • Cell suspension prepared to 1 ⁇ 10 6 cells / ml was seeded on a 48-well plate at 250 ⁇ l / well, and freeze-dried cells of various lactic acid bacteria and LPS (Wako) were added at the same time. Qing was recovered. Lyophilized dead cells were adjusted to 10 mg / ml with PBS, diluted with RPMI medium to each concentration, and added to cells at 125 ⁇ l / well.
  • LPS was adjusted to 1 mg / ml with distilled water, adjusted to 4 ⁇ g / ml with RPMI medium, and added to cells at 125 ⁇ l / well to a final concentration of 1 ⁇ g / ml.
  • IL-6, IL-10, and IL-12 (p40) concentrations in the collected supernatant were quantified using a mouse ELISA kit (Becton, Dickinson, and Company). Since the active form of IL-12 (p70) is not expressed in J774.1 cells, IL-12 (p40) was measured instead.
  • strain 17 and strain 23 the effect of three freeze-dried cells of strain 12 on the cytokine production ability of J774.1 cells was examined.
  • dead cells of strain 4 significantly enhance the ability of J774.1 cells to produce IL-12p40.
  • Strain 22 was predicted to have anti-inflammatory effects such as enhanced IL-10 production from the results of BMDC. Therefore, dead cells (1, 10 ⁇ g / ml) of the above 5 strains were added to J774.1 cells, and the production of IL-6, IL-10, IL-12 (p40) after 48 hours was measured by ELISA. The results are shown in FIGS. In FIGS.
  • control is J774.1 cells to which nothing is added
  • strain 12 is J774.1 cells to which dead cells of strain 12 are added
  • strains “17” is a J774.1 cell to which a dead cell of strain 17 is added
  • strain 23 is a J774.1 cell to which a dead cell of strain 23 is added
  • strain 22 is strain 22 In the case of J774.1 cells to which the dead cells were added
  • strain 4 is the case of J774.1 cells to which the dead cells of strain 4 were added.
  • Strain 4 had the highest production induction ability for any cytokine.
  • Strain 23 was found to have the same ability to induce IL-10 and IL-12 (p40) production as strain 22.
  • strain 23 exhibited a similar IL-10 production-inducing activity to BMDC as strain 22 which is an anti-inflammatory lactic acid bacterium with high immune activity.
  • dead cells of strain 23 showed IL-10 production-inducing activity comparable to that of strain 22 against J774.1 cells. That is, the strain 23 is considered to be an anti-inflammatory lactic acid bacterium having a high immune activity that is comparable to the strain 22.
  • strain 23 significantly increased adiponectin production relative to 3T3-L1 cells compared to other strains, and both in mouse bone marrow-derived dendritic cells and mouse macrophage J774.1 cells. It was revealed that the production of anti-inflammatory cytokines such as IL-10 was significantly increased compared to other strains. From this result, strain 23 not only improves the metabolic syndrome through enhancing the ability of adipocytes to produce adiponectin, but also enhances the ability to produce anti-inflammatory cytokines such as IL-10 secreted from immune system cells. This suggests an improvement effect on metabolic syndrome. This suggests that the fermentation product using strain 23 has an anti-metabolic syndrome effect.
  • Example 5 Efficacy Test Using Diabetes / Obesity Model Mice
  • KKAy mice in which the obesity-onset gene AY was introduced into KK mice were used.
  • KKAy mice are known to develop obesity, insulin resistance, and hyperlipidemia from a young age.
  • the number of strains 23 contained in the lactic acid bacteria culture was 2 ⁇ 10 8 cfu / ml.
  • the dosage of strain 23 culture in this study is 1 ⁇ 10 8 cfu / body / day (3.7 ⁇ 10 9 cfu / kg / day).
  • -Positive control drug Pioglitazone hydrochloride (Pioglitazone Hydrochloride, Funakoshi Co., Ltd.) was dissolved in carboxymethylcellulose sodium (Wako) solution, diluted with distilled water to 1 mg / ml, and used for administration.
  • Pioglitazone hydrochloride is a therapeutic agent for type 2 diabetes, which has been confirmed to suppress TNF ⁇ expression in adipose tissue, improve insulin resistance, and promote sugar uptake and utilization.
  • pioglitazone hydrochloride is 112529-15-4 and the chemical name is (5RS) -5- ⁇ 4- [2- (5-Ethylpyridin-2-yl) ethoxy] benzyl ⁇ thiazolidine-2, 4-dione monohydrochloride.
  • the dose of pioglitazone hydrochloride in this study is 0.5 mg / body / day. This dose was set with reference to the article by Mohapatra et al. (Mohapatra J, et al., Pharmacology. 84-4: 203, 2009).
  • the skim milk powder medium shown in Table 2 is given to the control group, the lactic acid bacteria culture is given to the lactic acid bacteria administration group, and the positive control drug is given to the positive control group once a day at 0.5 ml / body. did.
  • water was ad libitum and food was ad libitum CRF-1.
  • blood was collected from the tail vein once a week (day 0, day 7, day 14 and day 21) and fasted for 3.5 hours, and blood glucose level and hemoglobin A1c level were measured. After blood collection, CRF-1 was ingested freely.
  • body weight and food intake were measured twice a week (day 0, day 4, day 7, day 11, day 14, day 18, day 21) during the administration period of 3 weeks.
  • the patient was dissected after euthanasia by cervical dislocation, and the perirenal adipose tissue and epididymal adipose tissue were collected, each wet weight (g) was measured, and the total was taken as the visceral fat weight (g).
  • the adipose tissue was separated into a mature adipocyte fraction (MAF fraction) and a stromal blood vessel fraction (SVF fraction) by centrifugation, and the MAF fraction was analyzed for the expression level of adiponectin mRNA.
  • MAF fraction mature adipocyte fraction
  • SVF fraction stromal blood vessel fraction
  • -Blood glucose level Measured with a blood glucose measurement device (Breeze 2, Bayer Yakuhin).
  • Blood hemoglobin A1c (HbA1c) The concentration of hemoglobin A1c in blood was measured using a Hemoglobin A1c Testing Analyzer (DCA2000 system, Bayer Medical).
  • Blood adiponectin The concentration of adiponectin in blood was measured using a mouse adiponectin ELISA kit (Otsuka Pharmaceutical).
  • Blood triglyceride The blood triglyceride concentration was measured using Fuji Dry Chem System and Fuji Dry Chem Slide TG-PIII (Fuji Film).
  • Example 6 Production of yogurt A yogurt base mix was prepared according to a conventional method and mixed starter (Lactobacillus bulgaricus and Streptococcus thermophilus) and the mixed starter strain 23 (Lactobacillus plantarum OLL2712, (Accession number: FERM BP-11262)) was added and the inoculated one was fermented to produce yogurt. As a result, it was shown that the yogurt obtained by adding and inoculating the strain 23 had equivalent flavors and physical properties comparable to or higher than the yogurt obtained without addition.
  • Lactobacillus of the present invention in addition to increasing the production of adiponectin, it is also possible to increase the production of inflammatory immunity-related cytokines independent of adiponectin, a highly reliable complex Since the metabolic syndrome can be improved by a simple approach, it can be ingested easily and effectively by containing it in a pharmaceutical composition or food composition, and the metabolic syndrome can be improved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une nouvelle bactérie lactique capable d'améliorer un syndrome métabolique au moyen d'un nouveau procédé de criblage. La présente invention concerne spécifiquement : un Lactobacillus qui augmente la production de l'adiponectine dans des cellules 3T3-L1 et augmente la production d'une cytokine anti-inflammatoire dans des dendrocytes et/ou macrophages dérivés de moelle osseuse; une culture de Lactobacillus; et un protéine traitée de ladite culture. La présente invention concerne en outre une composition pour des aliments et une composition pharmaceutique qui contiennent le Lactobacillus, la culture, ou le produit traité mentionnés ci-dessus.
PCT/JP2011/067239 2010-07-30 2011-07-28 Bactérie lactique ayant un effet d'amélioration du syndrome métabolique Ceased WO2012014971A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201180037354.8A CN103314099B (zh) 2010-07-30 2011-07-28 具有代谢综合症改善效果的乳酸菌
HK13111466.7A HK1184187B (en) 2010-07-30 2011-07-28 Lactic bacterium having an effect of ameliorating metabolic syndrome
JP2011551729A JP5076029B2 (ja) 2010-07-30 2011-07-28 メタボリックシンドローム改善効果を有する乳酸菌

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010172256 2010-07-30
JP2010-172256 2010-07-30

Publications (1)

Publication Number Publication Date
WO2012014971A1 true WO2012014971A1 (fr) 2012-02-02

Family

ID=45530171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/067239 Ceased WO2012014971A1 (fr) 2010-07-30 2011-07-28 Bactérie lactique ayant un effet d'amélioration du syndrome métabolique

Country Status (3)

Country Link
JP (1) JP5076029B2 (fr)
CN (1) CN103314099B (fr)
WO (1) WO2012014971A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014031325A (ja) * 2012-08-02 2014-02-20 Maruzen Pharmaceut Co Ltd 抗炎症剤
JP2014172902A (ja) * 2013-03-05 2014-09-22 Shonan Institute For Medical & Preventive Science Ｌａｃｔｏｂａｃｉｌｌｕｓｐｌａｎｔａｒｕｍを用いたアカモク発酵物の糖尿病態改善剤
JP2017114814A (ja) * 2015-12-24 2017-06-29 丸善製薬株式会社 化粧料
CN111655839A (zh) * 2017-11-20 2020-09-11 庆熙大学校产学协力团 新型乳酸菌及其用途
JP2020203930A (ja) * 2020-09-09 2020-12-24 丸善製薬株式会社 化粧料
CN112190600A (zh) * 2020-09-11 2021-01-08 杭州娃哈哈科技有限公司 一株植物乳杆菌在制备缓解机体慢性炎症的组合物中的应用
JP2021023231A (ja) * 2019-08-07 2021-02-22 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
JP2021031408A (ja) * 2019-08-19 2021-03-01 株式会社明治 糖代謝改善用組成物
WO2021117857A1 (fr) 2019-12-13 2021-06-17 株式会社明治 Composition destinée à l'abaissement de la fréquence cardiaque
CN113637609A (zh) * 2021-08-17 2021-11-12 大连工业大学 一种降低乳蛋白抗原性的植物乳杆菌
WO2021261423A1 (fr) 2020-06-22 2021-12-30 株式会社明治 Composition destinée à favoriser la production d'interleukine-10
WO2022131192A1 (fr) * 2020-12-16 2022-06-23 株式会社明治 Composition pour atténuer l'inflammation d'un tissu cérébral
CN115287221A (zh) * 2022-06-13 2022-11-04 廖梅香 一株口乳杆菌及其应用
WO2023286754A1 (fr) 2021-07-12 2023-01-19 国立大学法人 東京医科歯科大学 Composition activant l'autophagie

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI589227B (zh) * 2011-12-06 2017-07-01 雪印惠乳業股份有限公司 加氏乳酸桿菌的存活性高的飲食品及其製造方法
CN107028985A (zh) * 2016-02-04 2017-08-11 深圳华大基因研究院 厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
JP7057059B2 (ja) * 2016-08-22 2022-04-19 株式会社明治 ラクトバチルス・プランタラムの培養物の製造方法
CN114763519B (zh) * 2021-01-12 2025-07-22 生合生物科技股份有限公司 食淀粉乳杆菌lam1345分离株及其用途
TWI776433B (zh) * 2021-03-22 2022-09-01 生合生物科技股份有限公司 戴白氏乳桿菌乳酸亞種ldl557分離株及其用途
CN114395514B (zh) * 2022-02-28 2023-09-01 鲁东大学 一株嗜酸乳杆菌、菌剂及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830750B1 (en) * 1998-10-01 2004-12-14 Probi Ab Reduction of oxidative stress factors with Lactobacillus plantarum
KR100686558B1 (ko) * 2004-09-02 2007-02-23 씨제이 주식회사 체지방 저하 기능성 락토바실러스 플랜타륨와 이를 함유한 식품

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AIRO TATEGAKI: "Ko-Tonyobyo Koka o Yushita Nyusankin", NIPPON NOGEI KAGAKUKAI TAIKAI KOEN YOSHISHU, vol. 2008, 2008, pages 152 *
DIAZ-ROPERO, MP ET AL.: "Two Lactobacillus strains, isolated from breast milk, differently modulate the immune response.", J APPL MICROBIOL., vol. 102, no. 2, February 2007 (2007-02-01), pages 337 - 343 *
WANG, B ET AL.: "Isolation of adhesive strains and evaluation of the colonization and immune response by Lactobacillus plantarum L2 in the rat gastrointestinal tract.", INT J FOOD MICROBIOL., vol. 132, no. 1, 1 June 2009 (2009-06-01), pages 59 - 66, XP026094586, DOI: doi:10.1016/j.ijfoodmicro.2009.03.016 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014031325A (ja) * 2012-08-02 2014-02-20 Maruzen Pharmaceut Co Ltd 抗炎症剤
JP2014172902A (ja) * 2013-03-05 2014-09-22 Shonan Institute For Medical & Preventive Science Ｌａｃｔｏｂａｃｉｌｌｕｓｐｌａｎｔａｒｕｍを用いたアカモク発酵物の糖尿病態改善剤
JP2017114814A (ja) * 2015-12-24 2017-06-29 丸善製薬株式会社 化粧料
CN111655839B (zh) * 2017-11-20 2023-01-20 庆熙大学校产学协力团 新型乳酸菌及其用途
CN111655839A (zh) * 2017-11-20 2020-09-11 庆熙大学校产学协力团 新型乳酸菌及其用途
JP2021023231A (ja) * 2019-08-07 2021-02-22 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
JP7013419B2 (ja) 2019-08-07 2022-02-15 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
JP7364390B2 (ja) 2019-08-19 2023-10-18 株式会社明治 糖代謝改善用組成物
JP2021031408A (ja) * 2019-08-19 2021-03-01 株式会社明治 糖代謝改善用組成物
WO2021117857A1 (fr) 2019-12-13 2021-06-17 株式会社明治 Composition destinée à l'abaissement de la fréquence cardiaque
JPWO2021117857A1 (fr) * 2019-12-13 2021-06-17
JPWO2021261423A1 (fr) * 2020-06-22 2021-12-30
WO2021261423A1 (fr) 2020-06-22 2021-12-30 株式会社明治 Composition destinée à favoriser la production d'interleukine-10
EP4212165A4 (fr) * 2020-06-22 2024-07-31 Meiji Co., Ltd Composition destinée à favoriser la production d'interleukine-10
JP7082827B2 (ja) 2020-09-09 2022-06-09 丸善製薬株式会社 化粧料
JP2020203930A (ja) * 2020-09-09 2020-12-24 丸善製薬株式会社 化粧料
CN112190600A (zh) * 2020-09-11 2021-01-08 杭州娃哈哈科技有限公司 一株植物乳杆菌在制备缓解机体慢性炎症的组合物中的应用
WO2022131192A1 (fr) * 2020-12-16 2022-06-23 株式会社明治 Composition pour atténuer l'inflammation d'un tissu cérébral
WO2023286754A1 (fr) 2021-07-12 2023-01-19 国立大学法人 東京医科歯科大学 Composition activant l'autophagie
CN113637609A (zh) * 2021-08-17 2021-11-12 大连工业大学 一种降低乳蛋白抗原性的植物乳杆菌
CN115287221A (zh) * 2022-06-13 2022-11-04 廖梅香 一株口乳杆菌及其应用

Also Published As

Publication number Publication date
HK1184187A1 (en) 2014-01-17
CN103314099B (zh) 2014-12-03
JPWO2012014971A1 (ja) 2013-09-12
CN103314099A (zh) 2013-09-18
JP5076029B2 (ja) 2012-11-21

Similar Documents

Publication Publication Date Title
JP5076029B2 (ja) メタボリックシンドローム改善効果を有する乳酸菌
JP5919193B2 (ja) 炎症を抑制する組成物
US9314041B2 (en) Immune function modulating agents
JP5527690B2 (ja) 免疫調節性機能誘導剤及び食品組成物
WO2009071086A2 (fr) Bactérie probiotique et régulation de l'accumulation de graisse
TW201705969A (zh) 新穎馬利乳酸桿菌ａｐｓ１及其用途
JP2023175938A (ja) 糖代謝改善用組成物
WO2012073924A1 (fr) Agent de prévention et/ou d'amélioration de l'endométriose, et composition pour aliment ou boisson le contenant
WO2015046407A1 (fr) Agent prophylactique contre des maladies immunologiques
JP5937015B2 (ja) 遅延型過敏症軽減剤
JP7606276B2 (ja) 脂質代謝改善用組成物
JP7181954B2 (ja) 高いＡｈＲ活性化能を有する乳酸菌
US20230058728A1 (en) Composition for reducing heart rate
HK1184187B (en) Lactic bacterium having an effect of ameliorating metabolic syndrome
JP5851242B2 (ja) チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および／または改善用の飲食品および医薬品
HK1200282B (en) Prophylactic agent for squamous carcinoma, squamous carcinoma model animal, and method for producing said model animal
HK1200282A1 (en) Prophylactic agent for squamous carcinoma, squamous carcinoma model animal, and method for producing said model animal
HK1184816B (en) Composition for preventing inflammations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2011551729

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11812560

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11812560

Country of ref document: EP

Kind code of ref document: A1